Chronic Inflammatory Demyelinating Polyneuropathy

Hizentra® in Inflammatory Neuropathies - pHeNIx Study
NCT04672733 | Observational

The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).

Trial Information
23 Sites
100 Participants
Recruiting
18 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

SUBMIT
CHU Angers
Angers,France,86000
Hpital priv de La Casamance
Aubagne,France,35760
CH Bayonne
Bayonne,France,67091
Hpital Pellegrin
Bordeaux,France,26000
CHRU Brest
Brest,France
Hpital Henri Mondor
Créteil,France
Hpital Bictre
Le Kremlin-Bicêtre,France
CH Libourne
Libourne,France
Hpital Roger Salengro, CHU Lille
Lille,France
Hpital Dupuytren
Limoges,France
Hpital Pierre Wertheimer,HCL
Lyon,France
Hpital de la Timone
Marseille,France
CHU Montpellier
Montpellier,France
CHRU Nancy
Nancy,France
CHU Nantes
Nantes,France
Hpital Pasteur
Nice,France
Hpital Lariboisire
Paris,France
La PitiSalptrire
Paris,France
CHU Poitiers
Poitiers,France
Hpital Charles Nicolle
Rouen,France
CHU SaintEtienne
Saint-Étienne,France
CHR Tours
Tours,France
CH de Valence
Valence,France

Study Eligibility Criteria

  • Adult patient (aged ≥18 years)
  • Patients suffering from CIDP according to EAN/PNS 2021 criteria
  • Planned switch from IVIg to Hizentra®
  • Patient treated with at least 3 courses of IV immunoglobulin and deemed by the investigator to be dependent on immunoglobulins
  • Patient deemed to be stable, with no change in their treatment for the disease during the 3 months prior to inclusion
  • Patients who have a smartphone, a tablet or a computer
  • Patients who have been informed verbally and in writing of the purposes of the study
  • Concomitant participation in an interventional clinical study

Additional Studies

Additional studies can be found at ClinicalTrials.gov